Abstract:
Objective：To observe the long-term efficacy of oral pidotimod combined with Kechuanling oral liquid in the treatment of children with mite allergic asthma.
Methods：The clinical data of 86 cases of allergic asthma were analyzed，and they were divided into two groups：the pidotimod combined with Kechuanling oral liquid in the treatment of 44 cases (combination group)，simple pidotimod treatment of 42 cases (single group)；they were followed up for 3 years. Compare the day and night symptom scores at the end of 2^nd and 3^rd year of treatment as well as the asthma exacerbation frequency during the 3^rd year of treatment.
Results:At the end of the second year and the end of the third year, the asthma symptoms score in the combination group was significantly lower than that of the single group, the difference being statistically significant(P＜0.05). The frequency of acute attack of the combination group was 27.27%(12/44), lower than that of the single group(57.14%，24/42), and the difference was statistically significant(P＜0.05).
Conclusion:Pidotimod combined with Kechuanling oral liquid in the treatment of mites allergic asthma can significantly relieve the symptoms of asthma in children and reduce asthmatic exacerbation frequency, with good long-term results and great clinical value.

Key words: asthma/allergic, pidotimod/treatment application, Kechuanling oral liquid/treatment application, children